JCM
CBMG

Jacobi Capital Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Jacobi Capital Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1
Closed – – 937
2017
Q2 		$0 Hold
1
– – ﹤0.01% 851
2017
Q1 		$0 Hold
1
– – ﹤0.01% 724
2016
Q4 		$0 Hold
1
– – ﹤0.01% 737
2016
Q3 		$0 Hold
1
– – ﹤0.01% 756
2016
Q2 		$0 Buy
+1
New +$16 ﹤0.01% 728

Other funds holding CBMG

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Jacobi Capital Management's CBMG Position: Q3 2017 in Review

Jacobi Capital Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2017, closing a stake of 1 share.

Jacobi Capital Management first reported a position in CBMG in Q2 2016 and held it in 5 quarters. The position peaked at $0 in Q2 2017. 20 funds tracked by Wall St. Rank hold CBMG as of Q3 2017.

  • Jacobi Capital Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2017 after selling out during the quarter.
  • Jacobi Capital Management sold 1 Cellular Biomedicine Group, Inc. share in Q3 2017.
  • Jacobi Capital Management first reported a position in Cellular Biomedicine Group, Inc. in Q2 2016 and held it in 5 quarters.
  • Jacobi Capital Management's Cellular Biomedicine Group, Inc. position peaked at $0 in Q2 2017.
  • 20 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2017.

Based on Jacobi Capital Management's 13F filing for Q3 2017, filed 2 Nov 2017.